Capstone Holding Corp.
CAPS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.7M
Close$
Share Statistics
| Market cap | $1.70 Million |
|---|---|
| Enterprise Value | $26.90 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.12 |
| Beta | -1.52 |
| Outstanding Shares | 9,329,828 |
Return
| Return on Equity | -197.11% |
|---|---|
| Return on Assets | -41.12% |
| Return on Invested Capital | -41.92% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | 0.63 |
| Price to Sales | 0.06 |
| Price to Book Ratio | 0.32 |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | -2.43 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.95 |
| Debt to Equity | 2.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 28, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$12.51 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$21.61 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Capstone Holding Corp.
36 employees
CEO: Matthew E. Lipman Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its a...